Aptose Biosciences (APTO) shares were down almost 23% in recent Wednesday trading even as the company said it initiated a new phase 1/2 study for newly diagnosed acute myeloid leukemia patients.
The company said it started the Tuscany phase 1/2 study to evaluate the dosage of a drug cocktail that includes tuspetinib combined with azacitidine and venetoclax. The drug trio is being developed as a front line treatment for acute myeloid leukemia, Aptose said.
Aptose said it expects to enroll 18 to 24 subjects in the study by mid-late 2025 across 12 planned sites in the US.
Price: 0.28, Change: -0.08, Percent Change: -22.72
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.